Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Wang, JieChen, Hongyu
Tang, Zihuan
Zhang, Jinquan
Xu, Yuanwei
Wan, Ke
Hussain, Kifah
Gkoutos, Georgios V
Han, Yuchi
Chen, Yucheng
Publication date
2023-08-24
Metadata
Show full item recordAbstract
Fifteen studies comprising 2765 patients (mean age 75.9 ± 9.3 years; 83.7% male) with a mean follow-up duration of 18.7 ± 17.1 months were included in the meta-analysis. There was a decrease in left ventricular ejection fraction (LVEF) (standard mean differences (SMD: -0.17; 95% confidence interval (CI), -0.31 to -0.03; P = 0.02) but were no significant differences in intraventricular septum (IVS) thickness or global longitudinal strain (GLS) after tafamidis treatment. However, subgroup analysis showed no significant deterioration in LVEF in the patients with wild-type ATTR after tafamidis treatment (SMD: -0.11; 95% CI, -0.34 to 0.12, P = 0.34). In addition, the group with tafamidis treatment had a decreased risk for all-cause death or heart transplantation compared to patients without treatment (the pooled RR, 0.44; 95% CI, 0.31-0.65; P < 0.01). Subgroup analysis showed that there was no significant difference of tafamidis on the outcomes in patients with wild-type or hereditary ATTR (RR, 0.44; 95% CI, 0.27-0.73 versus 0.21, 95% CI, 0.11-0.40, P = 0.08). Furthermore, tafamidis treatment was associated with a lower risk of the composite endpoint (RR, 0.57; 95% CI, 0.42-0.77; P < 0.01).Citation
Wang J, Chen H, Tang Z, Zhang J, Xu Y, Wan K, Hussain K, Gkoutos GV, Han Y, Chen Y. Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis. EClinicalMedicine. 2023 Aug 24;63:102172. doi: 10.1016/j.eclinm.2023.102172. PMID: 37662524; PMCID: PMC10474377.Type
ArticleAdditional Links
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00349-8/fulltextPMID
37662524Journal
EClinicalMedicinePublisher
Elsevierae974a485f413a2113503eed53cd6c53
10.1016/j.eclinm.2023.102172